Seeing Is Believing
Currently out of the existing stock ratings of Tejas Savant, 92 are a HOLD (37.25%), 12 are a SELL (4.86%), 143 are a BUY (57.89%).
Analyst Tejas Savant, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 36.53% that have a potential upside of 25.57% achieved within 112 days.
Tejas Savant’s has documented 503 price targets and ratings displayed on 34 stocks. The coverage is on Healthcare, Basic Materials, Industrials sectors.
Most recent stock forecast was given on TXG, 10X Genomics at 19-May-2025.
Analyst best performing recommendations are on CTKB (CYTEK BIOSCIENCES).
The best stock recommendation documented was for CTKB (CYTEK BIOSCIENCES) at 2/29/2024. The price target of $9 was fulfilled within 1 day with a profit of $1.3 (16.88%) receiving and performance score of 168.83.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$13
$4.07 (45.58%)
$11
18 days ago
(06-May-2025)
7/13 (53.85%)
$4.19 (47.56%)
100
Hold
$9
$0.07 (0.78%)
$10
19 days ago
(05-May-2025)
3/7 (42.86%)
$-1.03 (-10.27%)
189
Buy
$10
$1.07 (11.98%)
$9
22 days ago
(02-May-2025)
5/6 (83.33%)
$0.16 (1.63%)
96
Buy
$9
$0.07 (0.78%)
$8
5 months 6 days ago
(18-Dec-2024)
5/8 (62.5%)
$3.03 (50.75%)
108
Buy
$6
$-2.93 (-32.81%)
$8
9 months 22 days ago
(02-Aug-2024)
2/2 (100%)
$1.7 (39.53%)
222
Which stock is Tejas Savant is most bullish on?
Which stock is Tejas Savant is most reserved on?
What Year was the first public recommendation made by Tejas Savant?